Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Higher On Friday - ADMA Biologics (NASDAQ:ADMA), Argan (NYSE:AGX) U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earnings, raised dividend. Other gains: AGX 35.5%, MSC 24.5%, ADMA 13%, SGML 12.2%, KOD 10.5%, TBN 9.9%, METC 8.8%, U 8.3%, MEOH 7.7%, VOR 6.8%, Kopin Corp.

Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Higher On Friday U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earning...

#ADMA #AGX #big #gainers #KOD #KOPN #MEOH #METC #Mid-Day #Movers #MSC

Origin | Interest | Match

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research {"summary":"","positive":[],"negative":[],"faq":[]}

#ADMA ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

www.stocktitan.net/news/ADMA/adma-biologics...

ADMA Biologics Addresses Misleading Short-Seller Report {"summary":"","positive":[],"negative":[],"faq":[]}

#ADMA ADMA Biologics Addresses Misleading Short-Seller Report

www.stocktitan.net/news/ADMA/adma-biologics...

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#AFRM, #WDC, #NAVI, #ADMA, #USAR

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#MRK, #TMO, #NAVI, #HYMC, #ADMA

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ADMA 4.5x
2. #INVE 2.5x
3. #CCJ 2.2x
4. #ADBE 2.1x
5. #TOI 2.0x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ADMA, #INVE, #CCJ, #TOI, #CWST

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BMNR, #AG, #ADMA, #AXTI, #BE

#OptionFlow #OptionsTrading #Trading

ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative ADMA (Nasdaq: ADMA) announced a 2026 capital return initiative targeting $200 million, including a $125 million accelerated share repurchase (ASR) with JPMorgan, and plans to complete the ASR within about five months.The company will initially receive ~6.4 million shares (≈80% of expected ASR shares) based on a $15.57 close on Feb 27, 2026, and retains up to $500 million authorized repurchases.

#ADMA ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative

www.stocktitan.net/news/ADMA/adma-biologics...

Wärtsilä, Abu Dhabi Maritime Academy explore collaboration on maritime sustainability Wärtsilä and ADMA sign a 5 year MoU advancing #Decarbonisation, #SmartPorts and maritime training across the UAE, with MSRCAD advisory support. #Wärtsilä #ADMA #Sustainability #Shipping #EnergyEfficiency

Wärtsilä and ADMA sign a 5 year MoU advancing #Decarbonisation, #SmartPorts and maritime training across the UAE, with MSRCAD advisory support. #Wärtsilä #ADMA #Sustainability #Shipping #EnergyEfficiency

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ALAB, #CAPR, #MSTR, #GLXY, #ADMA

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ALAB 71% OTM
2. #CAPR 59% OTM
3. #MSTR 53% OTM
4. #GLXY 45% OTM
5. #ADMA 41% OTM

#OptionFlow #OptionsTrading #Trading

ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update ADMA (Nasdaq: ADMA) reported 3Q 2025 revenue $134.2M (+12% YoY), GAAP net income $36.4M, and Adjusted EBITDA $58.7M (+29% YoY). The company received FDA lot release for its first yield‑enhanced production batches, expected to drive gross margin expansion beginning in 4Q 2025 and through 2026. ASCENIV showed record utilization and a retrospective analysis reported infections falling from 2.1 to 0.9 per year (p<0.05). ADMA raised FY2025 revenue guidance to $510M+, FY2026 to $630M+, reaffirmed FY2025 Adjusted EBITDA at $235M, and raised FY2026 Adjusted EBITDA to $355M+. Company cites disciplined capital deployment, ongoing share repurchases, and SG‑001 pipeline upside.

#ADMA ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/ADMA/adma-biologics...

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ADMA 35.9x
2. #SMMT 24.1x
3. #CROX 18.1x
4. #FTNT 16.4x
5. #IOVA 11.3x

#OptionFlow #OptionsTrading #Trading

Adma Biologics (ADMA) Q2 Revenue Up 14% | The Motley Fool

#ADMA #06530743-76f6-4f43-a6c8-4f65ce948537 #data-news

Origin | Interest | Match

ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update ADMA Biologics (Nasdaq: ADMA) reported strong Q2 2025 financial results with total revenue of $122.0 million, up 14% year-over-year (29% excluding prior year non-recurring item). The company achieved GAAP net income of $34.2 million and Adjusted EBITDA of $50.8 million.Key developments include initiating commercial-scale manufacturing with an FDA-approved yield enhancement process delivering 20%+ increase in finished IG output, securing a $300 million syndicated debt refinancing led by J.P. Morgan, and expanding operations with a new Boca Raton facility acquisition that could increase cGMP manufacturing space by up to 30%.ADMA reaffirmed its guidance, projecting FY 2025 revenue over $500 million and FY 2026 revenue of $625+ million. The company expects to reach $1.1+ billion in annual revenue before 2030.

#ADMA ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/ADMA/adma-biologics...

Session: Nanomaterials to Advanced Materials: Challenges and Progress in Research, Industrial Application and Regulation.

Kai Paul is co-chair at SETAC EU Scientific Session – 15th May 2025.

Learn more >> www.bluefrogscientific.com/c...

#AdMa #Nano #NanoRegulation #SETAC #SETACEurope

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update ADMA Biologics reported strong Q1 2025 financial results with total revenue of $114.8 million, up 40% year-over-year. The company achieved GAAP Net Income of $26.9 million (51% YoY increase) and Adjusted EBITDA of $47.9 million (81% YoY increase). ADMA received FDA approval for its yield enhancement process, expected to increase production output by 20% from the same plasma volume.The company increased its guidance for FY 2025 and 2026, projecting total revenues of $500+ million and $625+ million respectively. ADMA authorized a $500 million share repurchase program, representing 8% of current market capitalization. The company's debt reorganization reduced cost of debt capital by 1.1%. ADMA now expects to achieve $1.1 billion in annual revenues before 2030, with anticipated margin expansion.

#ADMA ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/ADMA/adma-biologics...

ADMA Biologics Achieves Industry First: FDA Green Lights Revolutionary 20% Plasma Yield Enhancement First U.S. plasma producer secures groundbreaking FDA approval for 20% yield boost technology. Revenue acceleration expected late 2025. See growth projections.

#ADMA ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

www.stocktitan.net/news/ADMA/adma-biologics...

But overall, ADMA looks like it's on a serious growth trajectory.

Anyone else following this one? What are your thoughts on the sustainability of that revenue growth?

#ADMA #Stocks #Biotech #GrowthStocks #FinancialAnalysis #Trading

ADMA Biologics ($ADMA) is on 🔥 +22.2% in the last month, crushing the S&P 500 and its industry. Earnings estimates are getting bumped up – expecting $0.16/share this quarter (100% YoY growth!). Revenue projected to jump 45.5% to $119.1M. 👀 Looks like ADMA's got some serious momentum. #Biotech #ADMA

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ADMA 24.9x
2. #EA 16.3x
3. #BIDU 7.2x
4. #QSI 3.2x
5. #RXRX 2.9x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SNDK, #ADMA, #TEVA, #NTES, #CM

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #WOLF 10.6x
2. #VSCO 9.4x
3. #SNDK 8.2x
4. #GAP 7.1x
5. #ADMA 6.3x

#OptionFlow #OptionsTrading #Trading

ADMA Biologics Transforms: 65% Revenue Surge and First-Ever Annual Profit of $197.7M ADMA projects continued strong growth with 2025 revenue exceeding $490M and ambitious plans to reach $1B before 2030, supported by expanded plasma collection capacity.

#ADMA ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/ADMA/adma-biologics...

ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million YE 2024 Total Cash Grew to More than $100 Million, an Increase of Approximately $45 Million Q-o-Q, Notwithstanding $30 Million of Debt Organically Discharged During 4Q 2024

#ADMA ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update

www.stocktitan.net/news/ADMA/adma-biologics...

ADMA Biologics Accelerates Debt Reduction with $30M Term Loan Paydown, Slashes Total Debt 29% ADMA Biologics strengthens financial position with second major debt reduction in 4 months, using organic cash flow to optimize capital structure and boost earnings potential.

#ADMA ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility

www.stocktitan.net/news/ADMA/adma-biologics...